Literature DB >> 16488169

Computational study of human phosphomannose isomerase: Insights from homology modeling and molecular dynamics simulation of enzyme bound substrate.

Jingfa Xiao1, Zongru Guo, Yanshen Guo, Fengming Chu, Piaoyang Sun.   

Abstract

Phosphomannose isomerase is a zinc metalloenzyme that catalyzes the reversible isomerization of mannose-6-phosphate and fructose-6-phosphate, and the three-dimensional (3D) structure of human phosphomannose isomerase has not been reported. In order to understand the catalytic mechanism, the 3D structure of the protein is built by using homology modeling based on the known crystal structure of mannose-6-phosphate isomerase from (PDB code 1PMI). The model structure is further refined by energy minimization and molecular dynamics methods. The mannose-6-phosphate-enzyme complex is developed by molecular docking and the key residues involved in the ligand binding are determined, which will facilitate the understanding of the action mode of the ligands and guide further genetic studies. Our results suggest a hydride transfer mechanism of alpha-hydrogen between the C1 and C2 positions but do not support the cis-enediol mechanism. The detailed mechanism involves, on one side, Zn2+ mediating the movement of a proton between O1 and O2, and, on the other side, the hydrophobic environment formed in part by Tyr278 promoting transfer of a hydride ion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488169     DOI: 10.1016/j.jmgm.2006.01.001

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  2 in total

1.  ZIP10 is a negative determinant for anti-tumor effect of mannose in thyroid cancer by activating phosphate mannose isomerase.

Authors:  Sharui Ma; Na Wang; Rui Liu; Rui Zhang; Hui Dang; Yubo Wang; Simeng Wang; Zekun Zeng; Meiju Ji; Peng Hou
Journal:  J Exp Clin Cancer Res       Date:  2021-12-09

2.  Homology modeling a fast tool for drug discovery: current perspectives.

Authors:  V K Vyas; R D Ukawala; M Ghate; C Chintha
Journal:  Indian J Pharm Sci       Date:  2012-01       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.